Back to Trades
Total Value
$1.7M
Net $1.3M sold
Filing Date
Jun 26, 2026
2 transactions
Sales
$1.3M
2 transactions
Trade Summary
On Jun 25, 2026, Burrows Scott L, Chief Financial Officer, sold $1.7M of Spyre Therapeutics, Inc. (SYRE) across 2 transactions. The filing covers Common Stock and reflects net selling of $1.3M. Reported prices ranged from $14.50 to $87.14. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Spyre Therapeutics, Inc.
- Ticker Symbol
- SYRE
- CIK
- 0001636282
Insider Information
- Name
- Burrows Scott L
- Role
- Chief Financial Officer
- Location
- WALTHAM, MA
Filing Details
- Filing Date
- Jun 26, 2026
- Transaction Date
- Jun 25, 2026
- Accession Number
- 0001853327-26-000008
- Form Type
- 4
- Net Trading Amount
- -$1.3M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jun 25, 2026 | Common Stock | 15,000 | $14.50 | Exercise | $217.5K |
| Jun 25, 2026 | Common Stock | 5,000 | $87.12 | Sale | $435.6K |
| Jun 25, 2026 | Common Stock | 10,000 | $87.14 | Sale | $871.4K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jun 25, 2026 | SYRE derivative | 15,000 | $14.50 | Exercise | $217.5K |
Want live alerts when Burrows Scott L trades again?
Download Insider Trades to track SYRE, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.78 to $87.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- (F2)Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
- (F3)This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.